Claudia Rossig
University Children´s Hospital Münster
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Claudia Rossig as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07897968 · GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid TumorsUniversität Münster · not yet recruiting · Neuroblastoma (NBL), Ewing Sarcoma, Osteosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in ewing sarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 10:38 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.Pediatr Blood Cancer · 201843 citationsRCR 1.4